Vor Biopharma (VOR) Other financing activities (2020 - 2026)

Vor Biopharma (VOR) has reported Other financing activities for 6 consecutive years, with $75.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities changed N/A year-over-year to $75.0 million; the TTM figure through Mar 2026 stood at $249.4 million (up 1781321.43% YoY), while the FY2025 annual figure was $175.0 million, changed N/A from the prior year.
• Other financing activities retreated to $75.0 million in Q1 2026 per VOR's latest filing, from $174.4 million in the prior quarter.
• Across five years, Other financing activities topped out at $174.4 million in Q2 2025 and bottomed at $14000.0 in Q1 2023.
• Historically, Other financing activities has averaged $41.7 million across 4 years, with a median of $217000.0 in 2022.
• On a YoY basis, Other financing activities climbed as much as 100.12% in 2022 and fell as far as 99.89% in 2022.
• Vor Biopharma's Other financing activities stood at $234000.0 in 2022, then sank by 94.02% to $14000.0 in 2023, then surged by 1245614.29% to $174.4 million in 2025, then tumbled by 57.0% to $75.0 million in 2026.
• Business Quant data shows VOR's Other financing activities at $75.0 million in Q1 2026, $174.4 million in Q2 2025, and $14000.0 in Q1 2023.